Print

EASL - Gilead-BMS score all-oral hep C win but will pairing last?

Date April 19, 2012

Impressive cure rates for the combination of Gilead Sciences and Bristol-Myers Squibb's hepatitis C antivirals have emerged as the happy surprise of the EASL meeting. In a phase II study the interferon-free cocktail of GS-7977 and daclatasvir with ribavirin dosed for 24 weeks cured 100% of patients with the most prevalent type of the virus, genotype 1, and had near total cure rates without ribavirin.

Even a year ago, the promise of eliminating interferon, and its flu-like side effects, was thought to be many years away (EASL - Beyond protease inhibitors hep C pipeline filling up, April 4, 2011). However, specialists have significantly pushed up the timetable for elimination of the cytokine from the backbone of therapy: “The turnaround time for phase II and phase III studies has now accelerated enormously,” said Mark Thursz, secretary-general of EASL and a hepatology professor at Imperial College. “I can imagine the first interferon-free regimen being available within two years.”

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2014 EP Vantage Ltd